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1  | INTRODUC TION
One of the most prevalent immune cell populations in gut tissue 
are γδ T cells. γδ T cells represent a collection of diverse subsets 
with independent phenotypes and functions—some subsets reside 
in tissue-resident and other subsets circulate in blood. In humans, 
these subsets are defined by their expression of the δ chain (Vδ1, 
Vδ2, and Vδ3), whereas γδ T cell subsets in mice are characterized 
by the expression of the γ chain (Vγ1, Vγ4, Vγ5, Vγ6, and Vγ7). One 
interesting aspect of γδ T cells is that the γδTCR often dictates 
where the cells localize anatomically. Human Vδ1 and Vδ3 cells are 
frequently found in organs, including the gut, skin, and liver,1-3 while 
Vδ2 cells circulate in the peripheral blood. Similarly, mouse Vγ5, 
Vγ6, and Vγ7 cells are tissue-resident, whereas Vγ1 and Vγ4 cells 
traffic from tissue to lymph nodes. Human Vγ4Vδ1 cells and mouse 
Vγ7 cells account for the majority of gut-resident γδ T cells,1,4 but 
other subsets can infiltrate diseased, damaged, and dysplastic gut 
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Abstract
Colorectal cancer is the third most common cancer worldwide with nearly 2 million 
cases per year. Immune cells and inflammation are a critical component of colorectal 
cancer progression, and they are used as reliable prognostic indicators of patient 
outcome. With the growing appreciation for immunology in colorectal cancer, inter-
est is growing on the role γδ T cells have to play, as they represent one of the most 
prominent immune cell populations in gut tissue. This group of cells consists of both 
resident populations—γδ intraepithelial lymphocytes (γδ IELs)—and transient popula-
tions that each has unique functions. The homeostatic role of these γδ T cell sub-
sets is to maintain barrier integrity and prevent microorganisms from breaching the 
mucosal layer, which is accomplished through crosstalk with enterocytes and other 
immune cells. Recent years have seen a surge in discoveries regarding the regulation 
of γδ IELs in the intestine and the colon with particular new insights into the buty-
rophilin family. In this review, we discuss the development, specialities, and functions 
of γδ T cell subsets during cancer progression. We discuss how these cells may be 
used to predict patient outcome, as well as how to exploit their behavior for cancer 
immunotherapy.
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tissue. This review will focus on the development, phenotype, and 
function of both resident and infiltrating γδ T cells in the gut during 
cancer progression. We highlight the individual contribution of γδ T 
cell subsets in colorectal cancer (CRC), as well as strategies to boost 
their anti-tumor properties or methods to mitigate their pro-tumor 
functions. The role of γδ T cells in other cancer types has recently 
been reviewed elsewhere.5
2  | DE VELOPMENT OF CIRCUL ATING AND 
GUT-RESIDENT γδ  T  CELL S
γδ T cell generation in humans and mice is highly complex and tightly 
regulated. Recent years have seen a surge of new findings in this 
area. Here, we describe the aspects of γδ T cell development related 
to the subsets found in gut tissue. More detailed information can be 
found in recent review articles.6-8
In mice, the rearrangement of the Vγ4/5/6/7 locus is evident from 
embryonic day 12 (E12),9 preceding the start of αβ T cell develop-
ment at E17.10,11 E14 is just after completion of thymus development 
in the embryo, whereas hematopoiesis in the liver occurs from E12 
and then in the bone marrow from E16.5.12 Beginning at E12-E14, γδ 
T cells develop in ontogenic waves by functional subtype in the fetal 
thymus, starting with Vγ5 cells. Generation of Vγ5 cells is completed 
by E18.10,13 After Vγ5 cells, Vγ6 cells start to expand from E16 in mice 
followed by Vγ4 and Vγ1 cells.10,11,14,15 Recently, a monoclonal anti-
body specific for Vγ6 chain was developed, which has allowed the ac-
quisition of more specific information about Vγ6 cell development.15 
Vγ6 cells arise in the fetal thymus, like other subpopulations. Their 
numbers (together with Vγ5 cells) start diminishing after birth, while 
Vγ1 and Vγ4 cells continue to expand.15 Vγ5 cells, which express an 
invariant TCR chain, then migrate to the skin, proliferate within the 
skin, and exist there for their entire life as dendritic epidermal T cells 
(DETCs).16 Vγ6 cells also express a semi-invariant TCR,17,18 and these 
cells localize primarily to reproductive organs, tongue, and lung.19-21 
In adult mice, Vγ5 and Vγ6 cells (and some IL-17–producing Vγ4 cells 
in the colon) no longer require the thymus for development. They 
exist mostly as self-generating, tissue-resident cells.15,22-26 The de-
velopment of Vγ1 and Vγ4 cells in the thymus continues throughout 
adult life, where these cells emerge in a naive state, similar to αβ T 
cells. Vγ1 and Vγ4 cells travel throughout the body, and they are en-
riched in secondary lymphoid organs.27 Gene expression datasets, 
including single-cell sequencing, have provided more insight into the 
hierarchical development of γδ T cells in the thymus.28,29
The generation of γδ T cells in the fetal or adult thymus of mice 
results in two main functional populations—not including skin Vγ5 
cells or gut Vγ7 cells. These two groups of γδ T cells are defined 
by the cytokines they secrete, IFNγ and IL-17, rather than the TCR 
they express. IFNγ–producing γδ T cells are associated with Vγ1 
and Vγ4 TCRs, while IL-17–producing γδ T cells are associated with 
Vγ4 and Vγ6 TCRs. The programming of each effector population 
undergoes a distinct developmental process. Upon stimulation of 
γδTCR in thymic development, the common αβ/γδ precursors are 
committed into γδ T cell progenitors, upregulating CD24 as an im-
mature marker. After this, the fate of both effector types is also 
regulated by TCR stimulation, lymphotoxin, and IL-7 signaling.30-33 
Strong signaling on the γδTCR together with CD27 co-stimulation 
and lymphotoxin signaling directs progenitor cells into IFNγ–pro-
ducing γδ T cells, leading to downregulation of CD24 and CD25.30,31 
On the other hand, the development of IL-17–producing γδ T cells 
is dependent on weak TCR signaling, the lack of CD27 signaling, 
strong IL-7α signaling, and positive cues from the Notch path-
way.30,31,34-36 During this process, IL-17–producing γδ T cells lose 
CD27 expression and upregulate other receptors, such as CCR6 
and CD44.37 Certain transcription factors are required for the gen-
eration of IL-17–producing γδ T cells, such as RORγt, MAF, HES1, 
and STAT5.30,38-40 However, there are different developmental re-
quirements of transcription factors between IL-17–producing Vγ4 
and Vγ6 cells. For example, SOX4 and SOX13 are essential for the 
differentiation of Vγ4 cells, whereas they are dispensable for Vγ6 
cells.41 Conversely, PLZF is important for Vγ6 cells, but dispens-
able for Vγ4 cells.42 These data imply that IL-17–producing effec-
tor subsets are driven by both shared and discretely independent 
mechanisms. Whether these mechanisms are related to the timing 
of development—embryonic development (Vγ6) versus postnatal 
thymic development (Vγ4)—is unknown. In adult mice, three devel-
opmental pathways for γδ T cells have been identified that can be 
defined using CD24, CD25, CD73, CD117, CD200, and CD371.43
Human γδ T cells also develop in an embryonic wave.44,45 These 
cells emerge from the fetal or adult thymus as naive cells with polyclonal 
TCRs or imprinted effector cells, some of which express an invariant 
TCR.46-51 Interestingly, Vγ9Vδ2 cells generated during fetal develop-
ment are replaced by Vγ9Vδ2 cells with a different TCR in adults,52,53 
indicating a TCR switch of unknown importance. After birth, Vδ1 cells 
dominate γδ T cell development, overtaking Vδ2 cell numbers in the 
thymus, gut, and skin.45,54-57 With age, however, Vγ9Vδ2 cells expand 
to become the most abundant subset in the blood and spleen.
The origin of mouse liver-resident and gut-resident γδ T cells—
whose functions will obviously be important in primary CRC and liver 
metastasis—is somewhat unclear. Thus far, at least two subsets of 
liver-resident γδ T cells have been identified: one CD1d-expressing 
subset that produces IL-17 governed by lipid antigens from gut com-
mensal bacteria,58 and another CD8αα+ subset regulated by the MHC 
class I–related molecule, H2-Q10.59 Similar populations of resident 
cells are also found in human livers, characterized by the expres-
sion of Vδ1 as well as established resident markers, such as CD69, 
CXCR3, and CXCR6.3 However, the original source of γδ T liver cells 
in humans or mice is currently unknown. The origin of gut-resident 
γδ T cells is controversial. Rearrangement of the Vγ7 locus occurs 
as early as E11 in the liver and gut before T cell progenitors migrate 
into developing thymic lobes.9,60 Vγ7 cells can be exported from the 
fetal thymus during the perinatal period, and the adult thymus can 
generate Vγ7 cells.61-64 Thymic development of Vγ7 cells is depen-
dent on IL-15–activated STAT5.65 However, nude mice, which lack 
a thymus, still contain Vγ7 cells,1,66-68 and parabiosis experiments 
using adult mice have demonstrated that Vγ7 cells are rarely replaced 
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by circulating cells.69,70 The appearance of human gut Vγ4 cells may 
also occur independently of the thymus, but the ontogeny of these 
human cells is still not well addressed.71 Thus, the contribution of 
gut-resident γδ T cell development from the thymus seems minimal.
3  | LOC ATION AND FUNC TION OF γδ  T 
CELL SUBSETS IN THE GUT
Covering the surface of the intestinal lumen is a tight layer of epithelia 
organized as crypts and villi in the small intestine (SI) and crypts in the 
colon (Figure 1). This single layer of cells separates the gut tissue from 
digested food, dietary antigens, and microbes. Intestinal stem cells at 
the base of the crypts, marked by the leucine-rich repeat-containing 
G protein–coupled receptor 5 (Lgr5) protein, give rise to all types of 
intestinal epithelial cells (IECs), including enterocytes (or absorptive 
epithelial cells), goblet cells, enteroendocrine cells, Paneth cells, and 
Tuft cells.72 Lgr5+ stem cells divide about every 24 hours to self-main-
tain. These cells also exit the cell cycle, move upward toward the villus 
tip, and differentiate to replenish the various cell types that form the 
luminal layer of the gut. Once cells reach the top of the villus (except 
for Paneth cells) in a process that takes about 3-5 days, cells are most 
exposed to gut luminal contents and the microbiome. Tip cells undergo 
apoptosis and slough off into the lumen. The rapid turnover of new 
epithelial cells is necessary to prevent a break in the barrier.
Enterocytes are the most abundant cell type in the epithelium 
and form tight junctions with their neighboring cells to seal the bar-
rier. Enterocytes and goblet cells synthesize transmembrane mucins 
to protect apical surfaces and expedite food waste. Cells in the colon 
form two thick layers of mucus compared with the SI, and the mucus 
has a high viscosity with a gradient from proximal to distal. The 
mucus layer in the SI is much thinner but is augmented by anti-micro-
bial peptides (AMPs) synthesized by Paneth cells and enterocytes. 
Paneth cells are found only in the SI; the AMPs they produce include 
defensins, cathelicidin, lysozyme, and regenerating islet-derived pro-
tein 3 gamma (REG3G or REGIIIγ). In the colon, Paneth-like cells, also 
known as deep crypt secretory cells, support Lgr5+ stem cells, but it 
is unknown whether these cells can secret AMPs.73,74
The constituents of the microbiome are very different between 
the SI and colon. There is a gradient of bacterial load from proximal 
F I G U R E  1   T cell location in the 
intestine. Stem cells in the crypt 
receive support and survival cues 
from Paneth cells. These stem cells 
give rise to epithelial cells that line the 
gut and protect internal organs from 
microorganisms in the gut lumen. During 
differentiation, epithelial cells express 
BTNL1 in mice (and BTNL3 in humans), 
which localizes Vγ7 cells (or Vγ4 cells in 
humans) adjacent to epithelial cells and 
maintains their survival. αβ T cells that 
express CD8αα homodimers or CD8αβ 
heterodimers also reside next to epithelial 
cells. In the lamina properia, a variety of 
other γδ and αβ T cells traffic in and out 
of the tissue through blood vessels or 
lymphatic vessels. M cells, specialized 
epithelial cells, transport antigen to 
Peyer's patch, which contains mostly B 
cells and CD4 T cells
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to distal gastrointestinal tract: ordered by duodenum, jejunum, 
ileum, cecum, proximal colon, and distal colon.75 Bacterial load is 
much higher in the colon than the SI, partly because of the inhospita-
ble environment of the SI, which is more acidic and more abundant in 
AMPs than the colon.76 Therefore, it is easily presumed that immu-
nity in the SI and colon is suitably distinct. Coincidentally, human tu-
mors develop mainly in the colon and rarely in the SI. Accumulating 
evidence suggests that certain species of bacteria are associated 
with and drive CRC development.77
γδ T cells in the SI and colon serve as one of the first lines of de-
fense in the immune surveillance program of gut tissue (Figure 1). γδ 
T cells in this organ consist of both resident and infiltrating popula-
tions. The resident subset, called intraepithelial lymphocytes (IELs), 
roams up and down the villus along the basement membrane behind 
enterocytes in the lateral intercellular space that separates epithe-
lial cells from the lamina propria.78 IELs can express either a γδTCR 
or αβTCR, and these TCRs are oligoclonal in humans and mice.79-82 
γδ and αβ IELs that express the CD8αα co-receptor but not CD8β 
or CD4 are the so-called natural or type B IELs. SI enterocytes ex-
press the ligand for CD8αα, thymus leukemia antigen (TLA), which is 
a non-classical MHC class I molecule.83,84 There is another group of 
induced or type A IELs that arise from αβTCR-expressing T cells, and 
these cells can express CD4, CD8αα, and/or CD8αβ (not discussed 
further) [reviewed in Ref. 85]. γδ IELs account for 20%-30% of IELs in 
humans and about 50% of IELs in mice, where they express the Vγ4 
and Vγ7 chains, respectively.1,66,68,86
A few key molecules control the localization and active migra-
tion patterns of IELs. CD103, also known as αE integrin, is one of 
these molecules expressed by IELs. CD103 dimerizes with β7 inte-
grin, and this complex binds to E-cadherin on epithelial cells.87,88 In 
both CD103- and β7-deficient mice, IEL number is reduced with a 
greater reduction seen in β7-deficient mice.89,90 The milder effect 
of CD103 loss compared with β7 loss on IELs might be explained 
by the fact that β7 can form another heterodimer with α4 integrin, 
which is also involved in homing to the gut.91 Interestingly, αβ IELs 
are more affected by CD103 loss than γδ IELs. CD103 expression 
on IELs is stimulated by TGFβ and runt-related transcription factor 
3 (RUNX3),92,93 as well as by the CCL25-CCR9 axis.94,95 CCL25 is a 
chemokine highly expressed by SI epithelial cells,96 and its recep-
tor CCR9 is expressed on IELs.97 Despite ubiquitous expression of 
CCR9 by all IELs, CCL25- and CCR9-deficient mice exhibit a spe-
cific reduction in γδ IELs to half their number in wildtype mice.98,99 
CCR9 expression and IEL homing to SI seem to be regulated in part 
by the vitamin D receptor (VDR), as VDR knockout mice exhibit re-
duced CD8αα-expressing IEL that coincides with decreased IL-10 
levels.100 IL-15 is another key molecule that regulates both γδ and 
αβ IEL maintenance and localization.101-106 This cytokine and its re-
ceptor, IL-15Rα, are expressed by enterocytes and lamina propria 
DCs, where they form a complex that is transpresented to IELs. The 
use of sophisticated mouse models and advanced live cell imaging 
techniques has shown that IL-15 controls Vγ7 cell localization and 
migratory behavior within the lateral intercellular space, as blocking 
IL-15 signaling causes their patrolling nature to idle.104 In addition, 
the G protein–coupled receptor, GPR18, regulates γδ IEL abundance 
in the gut and this molecule is important for positioning of IELs next 
to epithelial cells as opposed to the lamina propria.107,108 By contrast, 
GPR55 negatively regulates γδ IELs, as confirmed by intravital im-
aging in GPR55-deficient mice that not only have more γδ IELs, but 
these cells also migrate faster and establish greater crosstalk with 
epithelial cells. Moreover, loss of GPR55 fails to affect αβ IELs.109 
Thus, αβ and γδ IELs share many similarities; however, their homing 
and motility are differentially regulated.
The phenotype of αβ and γδ IELs is very similar, almost indistin-
guishable in fact.110,111 Both αβ and γδ IELs express the semaphorin, 
CD100 (also called SEMA4D), which controls their proliferation.112 
Compared with other T cells, IELs exist in a constitutively active, 
cytolytic state with elevated effector potential. IELs constitutively 
express a number of cytolytic molecules, including granzymes A 
and B, perforin, and Fas ligand (FasL). Granzymes and perforin work 
together to penetrate the cell membrane of target cells and induce 
killing. FasL is a member of the tumor necrosis factor (TNF) ligand 
superfamily that binds Fas on target cells to trigger apoptosis. IELs 
also produce molecules normally associated with NK cells, such as 
2B4/CD244, NKG2A, NKG2D, NKp46, and NK1.1. IELs uniformly 
express CD69, an early activation marker of TCR activation as well 
as a tissue-resident marker.113,114 On the other hand, another marker 
of TCR stimulation, CD25, is scarcely expressed on IELs.110 Taken 
together, the phenotype of IELs indicates that these cells are always 
alert and poised for attack.
As suggested by their phenotype, the role of IELs in the gut is 
to maintain homeostasis and epithelial tight junction integrity [re-
viewed in Refs 91,115,116]. Crosstalk between the microbiome, 
epithelial cells, and IELs stimulates epithelial cell proliferation and 
function to reinforce the barrier.117 γδ IELs respond to microbiota 
through the Toll-like receptor (TLR)/MyD88 pathway that induces 
REGIIIγ to protect against invading bacteria.118 In chronic inflam-
matory diseases of the gut, including Crohn's disease and ulcerative 
colitis, loss of barrier integrity is accompanied by an influx of luminal 
pathogens, a subsequent massive immune response, and sustained 
tissue damage, illustrating the importance of intestinal homeostasis 
for the maintenance of a healthy gut. γδ IELs play a protective role 
in these pathologies by suppressing Th1 type responses.119,120 γδ T 
cell–deficient mice are susceptible to spontaneous colitis with age 
(5% of mice over 8 months old), as well as experimentally induced 
colitis. However, transfer of IELs into these γδ T cell–deficient mice 
reverses colitis, presumably through TGFβ–mediated suppression 
of IFNγ and TNF.119 By contrast, overactivation of γδ IEL is thought 
to perturb homeostasis in the gut, such as in inflammatory bowel 
disease (IBD) or celiac disease where elevated IL-15 expression is 
observed.121-125
In addition to human Vγ4 cells and mouse Vγ7 cells that con-
stitute the γδ IEL population, other γδ T cell subsets infiltrate the 
gut tissue (Figure 1). These cells expressing invariant or polyclonal 
γδTCR repertoires arrive via the blood or lymph system and land 
in the lamina propria.91,126 The lamina propria is the core of the 
villi that contains connective tissue, blood and lymphatic vessels, 
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fibroblasts, extracellular matrix, and a variety of immune cells. Gut-
infiltrating γδ T cells may acquire a cytotoxic, effector-like pheno-
type-like IELs, but other subsets express a completely different 
range of cytokines, such as IL-17 or IL-22. These cytokines, often 
in response to IL-23 and/or IL-1β, control the secretion of AMPs 
and tight junctions between enterocytes to sustain barrier func-
tion.25,127,128 In the mouse, IL-17- and IL-22–producing cells express 
either the Vγ4 or Vγ6 TCR. The abundance of these subsets changes 
between different regions of the gut with the highest enrichment of 
Vγ4 cells in the distal colon.25 IL-17- and IL-22–producing cells are 
negatively regulated by gut CD103+CD11b+ dendritic cells (DCs), 
since the depletion of this DC subset using Clec4a4-DTR mice re-
sults in higher IL-17 and IL-22 expression from γδ T cells—an affect 
not observed from CD4 T cells.25 Interestingly, there is a highly un-
usual population of mostly Vγ6 cells co-expressing IL-17, IL-22, and 
IFNγ found within the gut, which are not found in other tissues. 
Recent data show that STAT5 signaling controls the development 
of these polyfunctional cells, while STAT3 signaling controls IL-17 
and IL-22 expression and retinoic acid signaling controls IFNγ ex-
pression.38 However, it is unclear why these cells are unique to gut 
tissue or the purpose of their existence. Additionally, human lamina 
propria Vδ2 cells triggered by bacterial metabolites may reinforce 
barrier defense by recruiting neutrophils and stimulating CD4 T 
cells to produce IL-22.129,130
4  | γδ  T  CELL RECEPTOR STRUC TURE , 
ANTIGENS,  AND BINDING PARTNERS
Human TCRα (Chr14, q11.2), TCRβ (Chr7, q34), TCRγ (Chr7, p14), 
and TCRδ (Chr14, q11.2) are encoded in the genome by several seg-
ments for each variable (V), diversity (D), joining (J), and constant 
(C) segments. Human TCRγ and TCRδ contain 6 and 8 functional V 
segments, respectively (5 of the 8 V segments of TCRδ are shared 
with TCRα), while TCRα and TCRβ contain 41 and 30 V segments, 
respectively.131 So, γδTCRs seem to have much smaller repertoire 
potential than αβTCRs.
A few studies have reported on the structure of various γδT-
CRs.132-139 In comparison with the αβTCR, the V regions of the γδTCR 
are similar, whereas the C regions are substantially different.134 The 
antigen-binging domain of γδTCR has more protrusions and clefts, 
exhibiting more similarity to the surface of immunoglobulin heavy 
chain (VH) than to the αβTCR, which has a flat surface. The deter-
minant for antigen binding lies within amino acid sequences sepa-
rated into 3 regions called complementarity-determining regions 
(CDRs). CDR1 and CDR2 are germline-encoded loops derived from 
the V segment, and CDR3 forms loops from the recombined region 
around the junction of the V, D, and J segments. CDR3 forms the 
center of the antigen-binding site. Interestingly, the length of the 
CDR3 of TCRδ is as very variable and long as that of VH,
140 indicat-
ing that the γδTCR is closer related to immunoglobulins than TCRα 
and thus can recognize a variety of antigen types. The more strik-
ing difference between γδTCRs and αβTCRs is observed in the C 
domain, where angles, glycosylation sites, and charges of residues 
are distinct. Given that the C domain binds CD3 subunits, these dif-
ferences suggest that the association with CD3 subunits and subse-
quent intracellular signaling may be different to that of αβTCR. This 
view is supported by biochemical assays and knockout mice, which 
have demonstrated that most mouse γδTCRs do not associate with 
the CD3δε heterodimer, but with two CD3γε heterodimers.141-143 
However, thymic γδ T cells from Cd3d+/−Cd3g+/− mice exhibit reduced 
γδTCR expression with dysfunctional differentiation into IFNγ–pro-
ducing γδ T cells,144 indicating that the CD3δε heterodimer is import-
ant for some γδTCRs. Human γδTCRs are entirely reliant on CD3δε 
and CD3γε heterodimers.143
Antigens and ligands for γδTCRs constitute a wide variety of 
unconventional molecules. An important distinction between γδT-
CRs and αβTCRs is that γδTCRs do not bind major histocompatibility 
complex (MHC) molecules, and γδ T cells rarely express CD4 or CD8 
MHC co-receptors (except in the case of gut-resident γδ T cells as 
discussed above). This major difference between T cell populations 
has contributed to the poorly understood nature and biology of γδ T 
cells over the last decades. However, recent work is uncovering new 
information in this elusive area [reviewed in Ref. 145].
γδTCR antigens fall into two main categories: adaptive-like mol-
ecules and B7-like molecules with similarity to the CD28 co-stimula-
tory receptor. Circulating γδ T cells in both humans and mice can bind 
the self-stress molecule endothelial protein C receptor (EPCR),146,147 
phycoerythrin,148 and MHC class I–like molecules, such as T10, T22, 
MR1, CD1c, and CD1d.135-137,139,149-156 T10 and T22 are only ex-
pressed in mice. Human γδ T cells can also recognize annexin A2.157 
γδTCRs recognize several of these molecules independently of pep-
tides or lipids or metabolites, except in the case of the CD1 family 
that presents lipids and MR1 that presents metabolites, although the 
requirement of lipids and metabolites for interaction between γδT-
CRs and CD1c/d or MR1 is unknown. It should be noted that only a 
small frequency of γδTCRs binds the various molecules listed above, 
leaving unanswered questions about what other adaptive-like mol-
ecules interact with the majority of γδTCRs. Members of the butyr-
ophilin (BTN) and butyrophilin-like (BTNL) family make up the other 
category of γδTCR antigens. The BTN/BTNL family of proteins is 
structurally and phylogenetically related to the B7 superfamily of 
co-stimulatory molecules, encompassing B7.1 (CD80), B7.2 (CD86), 
CD28, CTLA-4, PD-L1, and PD-L2.158,159 In humans, circulating 
Vγ9Vδ2 cells recognize the BTN3A1-BTN2A1 heterodimer, a recep-
tor complex that acts as a sensor for a group of pyrophosphate-con-
taining metabolites called phosphoantigens that may be endogenous 
or exogenous (ie, non-self, microbial-derived) products.160,161 Some 
of these phosphoantigens include isopentenyl pyrophosphate (IPP) 
generated from the mevalonate pathway important for cholesterol 
biosynthesis 162,163 or the microbial hydroxyl-methyl-butyl-py-
rophosphate (HMBPP) metabolite produced from the isoprenoid 
pathway.164 BTN3A1 and BTN2A1 sense the accumulation of intra-
cellular phosphoantigens such as IPP and HMBPP, and binding of 
these phosphoantigens to intracellular domains of BTN3A1 causes 
a conformational change in the protein, promoting recruitment of 
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BTN2A1 that directly binds the Vγ9Vδ2 TCR.161,165-167 The buildup 
of IPP is a common occurrence in many types of cancers with dys-
regulated metabolism, making cancer cells amenable to Vγ9Vδ2 cell 
killing. The role of BTN/BTNL family members in regulating resident 
γδ T cell subsets is discussed below.
Pioneering work on thymic development and maturation of 
mouse skin-resident Vγ5 cells led to the first link between BTN/
BTNL family members and γδ T cells. This discovery identified 
SKINT1, which is a BTN/BTNL family member specifically expressed 
in the skin and thymus, as a crucial protein for Vγ5 cell expansion 
during development and survival in skin.168-170 More recently, mouse 
BTNL1 and human BTNL3 were demonstrated to be the equivalent 
of SKINT1 for gut Vγ7 and Vγ4Vδ1 IELs, respectively.1 These BTNL 
family members are expressed solely in the SI and colon.171 Btnl1-
deficient mice display a marked reduction in Vγ7 cells in gut tissue. 
BTNL1 dimerizes with BTNL6, and BTNL3 dimerizes with BTNL8 
to maintain γδ IEL survival and function in both humans and mice, 
indicating a highly conversed network between species. In subse-
quent studies, mutagenesis, computational modeling, and functional 
assays showed that the Ig-V regions of BTNL3 directly interact with 
the germline-encoded non-variable regions of the Vγ4 TCR.172,173 
These data uncover a unique ability of γδTCRs to recognize and 
respond to ligands via variable and non-variable sequences. Given 
these sophisticated properties of combining innate and adaptive 
traits at the cell-intrinsic level, the term “adaptate” was coined to 
better represent γδ T cell biology.174,175
5  | COLOREC TAL C ANCER ETIOLOGY AND 
MODELING IN MICE
Colorectal cancer is the third most common cancer in men and sec-
ond most common in women worldwide,176 rising from fourth and 
third most common in 2002,177 respectively. CRC is estimated to 
kill over 881 000 people worldwide.176 Incidence and mortality are 
likely to increase as life expectancy rises and developing countries 
become increasingly westernized. Key risk factors for CRC include 
increased red meat consumption, low fiber intake, and a low level of 
physical activity.178-180
The progression from adenoma to CRC is driven by the acqui-
sition of multiple genetic aberrations. There are two types of ad-
enomas whose genetic mutations differ that correspond with two 
postulated avenues to metastatic CRC. In the case of sessile serrated 
polyps (SSPs), mutational drivers consist of BRAF mutations, CpG 
island methylator phenotype (CIMP), and microsatellite instability 
(MSI).181,182 In contrast, traditional serrated adenoma conversion to 
carcinoma is driven by mutation of the tumor suppressor protein, 
APC, the inactivation of which allows for stabilization and transloca-
tion of β-catenin to the nucleus where it participates in upregulation 
of WNT target genes.183,184 Further mutations occur in KRAS, TGFβ 
signaling, and p53, leading to progression of the tumor,185-188 and 
may be influenced by MSI.189 Although significant hereditary fac-
tors are present in approximately 35% of CRC incidence,190 driver 
mutations in genes causing established hereditary syndromes ac-
count for approximately 5% of CRC incidence.191,192 The most prev-
alent of these hereditary syndromes is Lynch syndrome,193,194 driven 
by a mutation in genes that jeopardize DNA mismatch repair (MMR), 
such as MLH1, MSH2, MSH6, and PMS2.195-203 The remaining he-
reditary syndromes are associated with severe polyposis and subse-
quently an increased likelihood of progression from the polyp stage, 
such as Peutz-Jeghers syndrome,204 familial adenomatous polyposis, 
and other adenomatous polyposis syndromes.205
In 2015, a consortium of CRC scientists agreed on a set of four 
molecular subtypes derived from gene expression data, termed 
consensus molecular subtypes (CMS).206 The authors produced 
the CMS subtypes from over 3000 patients to determine biologi-
cal characteristics associated with each CMS subtype. CMS1, the 
immune-related group, is characterized by MSI and high immune 
infiltrate, in addition to high CIMP, BRAF mutations, activation of 
the JAK/STAT pathway, and an intermediate overall survival. CMS2, 
the canonical subtype, is characterized by high DNA somatic copy 
number alterations (SCNA), low immune infiltrate and stromal in-
vasion, activation of WNT signaling, and the best overall survival. 
CMS3 is characterized by mutations in KRAS, low immune infiltrate 
and stromal invasion, activation of metabolic genes, and an interme-
diate survival. CMS4 is characterized by high SCNA, high stromal 
invasion, activation of the TGFβ and VEGF pathways, and the worst 
overall survival. These CMS subtypes were developed from whole 
tumor tissue, which may be confounded by stroma and immune cell 
composition. Other attempts at refining transcriptional gene signa-
tures using cancer cell–intrinsic gene expression have made valuable 
improvements to the CMS stratification; this approach was named 
CRIS for CRC intrinsic signature.207 Incidentally, CMS4 and CRIS-B 
share the same TGFβ–enriched pathways, so there is a degree of 
overlap between methodologies. Given the difficulty in translating 
transcriptomics into routine pathology as well as the costly nature 
of generating and analyzing gene expression data for every patient 
with CRC, we developed a phenotypic subtyping method based on 
the CMS subtypes with the aim of introducing histology-based sub-
typing into clinical practice.208,209 This method incorporates immune 
cell infiltration using the Klintrup-Mäkinen (KM) grade, proliferation 
of cancer cells using the Ki-67 marker, and stromal invasion using 
the tumor-stroma percentage.209 These measures produce four 
phenotypic subtypes: immune, canonical, latent, and stromal. The 
phenotypic subtypes are prognostic classifiers in stage I-stage III 
CRC independent of TNM staging and predict recurrence and che-
motherapy response.208 Taken together, these approaches provide 
robust classification systems for CRC and opportunities for person-
alized anti-cancer therapy and immunotherapy.
In the quest to understand the etiology and biology of CRC, can-
cer researchers are developing increasingly accurate ways to model 
colorectal cancer that mirror the CMS phenotyping. Since APC al-
terations are the most common mutations in colorectal cancer,188 
mouse models have historically relied on APC mutations,210 such as 
the ApcMin/+ model, which carries a point mutation in Apc.211 Models 
of this type readily develop sporadic polyps. However, there are 
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drawbacks to Apc mutant models, including their predilection for SI 
tumors rather than colonic tumors as seen in humans, and the low 
penetrance of advanced carcinomas. The development of mouse 
models looking beyond APC mutations in isolation, thus better re-
flecting the progressive series of mutations seen in CRC, and the 
subsequent engineering of mouse models which reflect the most 
up-to-date CRC subtyping method allow researchers to study CRC 
in a more relevant context. Some examples include advances in or-
ganoid technology, which can be transplanted into syngeneic or im-
munodeficient mice, and new genetically engineered mouse models 
that fully recapitulate CRC progression from adenoma to metasta-
sis.212-215 However, the use of these models either older or newer 
in γδ T cell biology is limited. The importance of γδ T cells in CRC is 
discussed next.
6  | THE ROLE OF ANTI-TUMORIGENIC γδ 
T  CELL S IN CRC
The anti-tumorigenic function of γδ T cells in mice was first observed 
in 2001, showing in carcinogen-induced mouse models that cutane-
ous Vγ5 cells (DETCs) regulate skin cancer growth in a manner de-
pendent on NKG2D recognition of the stress ligand, RAE-1.216 The 
anti-tumorigenic role of both human and mouse γδ T cells has since 
been expanded to multiple cancer types [reviewed in Ref. 5]. Much 
of the evidence for an anti-tumorigenic role for human γδ T cells spe-
cifically in CRC is related to their functional ability to kill established 
CRC cell lines, taken from patients with advanced disease (discussed 
further below). However, there is some evidence that γδ T cells play 
a protective role in earlier stages of disease progression and even 
tumor initiation from mouse models. For example, in a mouse model 
of hypocholesteremia (ApoE-deficient mice) given the carcinogen, 
azoxymethane (AOM), tumor incidence and severity are associated 
with decreased numbers of γδ T cells.217 Here, hypocholesteremia 
adversely impacts hematopoietic stem cells, skewing differentiation 
away from γδ T cell and NK cell development. Indeed, mice lacking 
γδ T cells exhibit greater numbers of AOM-induced gut tumors.217,218 
Together, these data suggest that γδ T cells are important in immune 
surveillance during the early stages of CRC disease progression. 
Whether thymic-derived γδ T cells or γδ IEL or both play a role in 
counteracting gut tumor progression is unclear.
Circulating human Vγ9Vδ2 cells have so far been the focus of 
research into the killing ability of γδ T cells across multiple cancer 
types. Transcriptomic analysis of Vγ9Vδ2 cells has shown that this 
subset expresses of blend of αβ T cell, NK cell, and MAIT cell gene 
signatures.219,220 Interestingly, Vγ9Vδ2 cells produce higher levels of 
NKG2D, NKG2A, granzyme B, FasL, and several DC-related cyto-
kines and chemokines than αβ T cells or NK cells.219 Vγ9Vδ2 cells 
can kill a variety of CRC cell lines, regardless of whether these cells 
were isolated from the ascites of a metastatic CRC patient, the pri-
mary tumor of a CRC patient, or the peripheral blood of a healthy 
donor.221 The equivalent cytotoxic capacity of Vγ9Vδ2 cells from 
cancer patients and healthy donors suggests that tumors fail to 
negatively influence the anti-tumorigenic properties of circulating 
Vγ9Vδ2 cells. However, when γδ T cells are cocultured with super-
natants from CRC patient–derived cancer stem cells (CSCs) or can-
cer-associated fibroblasts (CAFs), the proliferation of γδ T cells and 
IFNγ expression is reduced, while IL-17 expression is increased.222 
These observations indicate that the tumor microenvironment may 
influence the ability of γδ T cells to recognize cancer cells. In support 
of this notion, the characterization of Vγ9Vδ2 cells in CRC patients 
with liver metastasis treated with standard of care, 5-fluorouracil/
oxaliplatin (FOLFOX), has shown that absolute numbers of circulat-
ing Vγ9Vδ2 cells are reduced.223,224 Vγ9Vδ2 cells in these patients 
exhibit a higher frequency of terminally differentiated and senes-
cent phenotype with impaired effector function, when compared 
to Vγ9Vδ2 cells from healthy donors. In addition, the number of 
chemotherapy cycles is correlated with a decrease in Vγ9Vδ2 cells 
expressing central memory markers, and chemotherapy also skews 
Vγ9Vδ2 cells toward terminal differentiation.223 However, whether 
this change in Vγ9Vδ2 cell effector function adversely impacts prog-
nosis or patient survival is unknown.
As discussed above, metabolites of the mevalonate pathway 
such as isopentenyl pyrophosphate (IPP) activate Vγ9Vδ2 cells 
via recognition of the BTN3A1-BTN2A1 heterodimer on cancer 
cells.160,161,165-167 Blocking the mevalonate pathway to inhibit IPP ac-
cumulation in cancer cell lines reduces Vγ9Vδ2-mediated cell lysis.221 
Conversely, the use of nitrogen-containing bisphosphonates, such as 
zoledronate, to increase IPP accumulation in CRC stem cells, sensi-
tizes cancer cells to Vγ9Vδ2-induced cytotoxicity.225,226 These data 
underscore the importance of IPP-stimulated BTN3A1-BTN2A1 
receptors in Vγ9Vδ2 cell recognition of CRC, although it is unclear 
whether the mevalonate pathway and IPP accumulation are dys-
functional in every subtype of CRC.
Despite a large focus of γδ T cell research centered on Vγ9Vδ2 
cells, of increasing interest are the Vδ2— subsets, particularly the Vδ1 
cells. Vδ1 cells are the dominant population in human colorectal tu-
mors,222 and these cells display cytolytic reactivity against CRC cell 
lines both in vitro and in a xenograft model.227-230 Killing of cancer 
cells by Vδ1 cells is independent of MHC molecule recognition.228 
Interestingly, one study reported that the cytotoxic ability of Vδ1 
cells from the primary tumor of three CRC patients (one metastatic) 
is markedly higher against epithelial tissues than alternative tissues 
such as hematopoietic cancer cell lines, as quantified by percent-
age cell lysis and IFNγ release.227 Thus, Vδ1 cells may be reacting 
to a ligand which is native to epithelial tissues by a receptor that 
is constitutively expressed on these cells, such as NKG2D.114,133,231-
234 In comparisons between Vδ1 cells and Vδ2 cells isolated from 
peripheral blood of healthy donors and CRC patients, Vδ1 express 
higher levels of activation markers, cytotoxicity markers, and termi-
nal differentiation markers. This apparent difference in phenotype 
is also observed functionally, as Vδ1 T cells induce greater lysis of 
CRC cell lines than did Vδ2 T cells.228,229 As interest in Vδ1 cells con-
tinues to grow, research is beginning to elucidate more specific de-
tails about these cells, how they differ from Vδ2 cells, and ultimately 
how they function. An NKp46+ subpopulation of IELs that mostly 
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consist of Vγ4Vδ1-expressing cells has recently been character-
ized.114 The abundance of these cells is less in stage III/IV than stage 
I/II. After coculture with the myelogenous leukemia cell line K562, 
the NKp46+ γδ T cells produce more IFNγ, granzyme B, and CD107a 
than the NKp46— population and kill K562 cells more efficiently. 
Blocking NKp46 also reduces K562 killing in these cocultures.114 
Collectively, Vδ1 appear to demonstrate a stronger anti-tumorigenic 
potency than their Vδ2 counterparts. The anti-tumorigenic roles of 
γδ T cells are summarized in Figure 2.
The majority of cancer deaths are a consequence of metastasis 
so understanding how γδ T cells may counter the metastatic pro-
cess is of great interest. In an orthotopic mouse xenograft model of 
luciferase-expressing HT29 cells injected into the cecum of immu-
nodeficient mice, the administration of Vδ1 T cells reduces primary 
tumor growth as well as the formation of spontaneous liver and lung 
metastases. Similarly, Vδ1 cell immunotherapy decreases HT29 cell 
growth in the lung after intravenous injection.235 Thus, Vδ1 cells 
counteract CRC growth regardless of a tumor's anatomical location, 
indicating that Vδ1 cells not only exhibit anti-tumor potential but 
also anti-metastatic potential.
7  | THE ROLE OF PRO -TUMORIGENIC γδ  T 
CELL S IN CRC
The knowledge of how γδ T cells may promote CRC is still limited, but 
what is known is largely centered on IL-17–producing γδ T cell subsets 
(Figure 3). This is also true for other tumor types, where we and oth-
ers showed that IL-17–producing γδ T cells drive cancer progression 
and metastasis.236-240 In mouse models driven by mutant Apc or loss 
F I G U R E  2   Anti-tumorigenic functions of γδ T cells in colorectal cancer. In humans, two major subsets of γδ T cells can recognize and 
kill cancer cells: One is the gut-resident Vδ1 cell subset and the other is the Vγ9Vδ2 cell subset that enters the gut from the circulation. 
Both subsets express cytotoxic molecules, such as granzyme, perforin, FasL, IFNγ, and TNF. During immunosurveillance, γδ T cells may 
sense abnormalities through the NKG2D receptor by stress ligands expressed on cancer cells. Vδ1 cells that express the Vγ4 chain (or 
Vγ7 chain in mice) and NKp46 may bind cancer cells through BTNL3 (or BTNL1 in mice). By contrast, Vγ9Vδ2 cells recognize cancer cells 
through BTN3A1/BTN2A1 heterodimers, which bind to the γδ T cell receptor (TCR) after activation by the IPP metabolite, a product of the 
mevalonate pathway
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of Apc, inflammation activated through the Toll-like receptor (TLR) 
pathway plays a central role in tumorigenesis.241,242 When MyD88, an 
adapter molecule through which TLR signaling is mediated, is deleted 
in these Apc models, tumor formation and pro-inflammatory mole-
cules including COX-2, IL-6, IL-23, and IL-1β are reduced. Microbial 
products exposed to myeloid cells via breakdown of the epithelial 
barrier trigger these pro-inflammatory molecules and potentiate can-
cer progression. These events converge on the upregulation of IL-17A 
in CD4 T cells (ie, Th17 cells) and/or γδ T cells. The importance of IL-
17A signaling in Apc models has been shown by deleting the Il17a or 
Il17ra genes, which phenocopy the decrease in tumor incidence seen 
in MyD88-deficient mice.242-244 IL-17A functions directly on APC-
deficient enterocytes to stimulate their proliferation through activa-
tion of MAPK signal transduction pathways.244 Genetically deleting 
the cellular source of IL-17A—either αβ T cells or γδ T cells—abrogates 
tumor formation in ApcMin/+ mice.245 Taken together, these studies 
indicate that inflammation directed through TLR-mediated activation 
of IL-17–producing CD4 T cells and γδ T cells promotes CRC develop-
ment. These IL-17–producing γδ T cells are likely Vγ4 or Vγ6 cells, as 
Vγ7 IELs are not capable of making IL-17.
Like the Apc models of CRC, Th17 cells and IL-17–producing γδ T 
cells are increased in enterotoxigenic Bacteroides fragilis (ETBF)–in-
duced mouse models of CRC.246-248 Unlike the ApcMin/+ model, how-
ever, Th17 cells and IL-17–producing γδ T cells are redundant in this 
context. Inhibiting the function of Th17 cells via STAT3 depletion 
fails to prevent tumorigenesis, because γδ T cells also express IL-17A. 
To prevent tumor formation in the ETBF model, both Th17 cells and 
γδ T cells must be ablated.247 This redundancy is not observed in 
F I G U R E  3   Pro-tumorigenic functions of γδ T cells in colorectal cancer. Breakdown of the epithelial barrier by the disorganization of 
cancer cells allows bacteria to penetrate gut tissue. These microorganisms activate dendritic cells (DC) and macrophages to secrete the 
cytokines, IL-1β and IL-23, which are received by γδ T cells expressing Vγ6 or Vγ4 cells (in mice or Vδ1 cells in humans). In response to this 
stimulus, these γδ T cell subsets release IL-17A, and IL-17A can induce proliferation of cancer cells or induce G-CSF expression by other 
cells. G-CSF mediates neutrophil expansion; neutrophils are drawn into the tumor microenvironment by the chemokines, CXCL1, CXCL2, or 
CXCL5. Neutrophils and γδ T cells can suppress the anti-tumor activity of CD8 T cells to promote cancer progression
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every mouse model of cancer. In the K14-Cre;Cdh1F/F;Trp53F/F model 
of breast cancer, we found that both CD4 T cells and γδ T cells in-
crease expression of IL-17A in response to tumor-associated mac-
rophage-derived IL-1β; however, the depletion of Th17 cells failed 
to reduce pro-metastatic neutrophils.236,249 These data indicate that 
IL-17–producing γδ T cells are the dominant pro-tumorigenic popula-
tion in this model. γδ T cells are also dominant over CD4 T cells in the 
KrasG12D;Trp53F/F lung cancer model. γδ T cells, not CD4 T cells, up-
regulate IL-17A to drive cancer progression, after bacterial-induced 
IL-23 and IL-1β expression.250 It is unclear how CD4 T cells and γδ T 
cells are differentially regulated in these contexts, when both cell 
types can be induced to make IL-17A by the same mechanisms. On 
a per cell basis, γδ T cells express higher levels of IL-17A than CD4 T 
cells. Thus, targeting IL-17A rather than Th17 cells or IL-17–producing 
γδ T cells may be a more viable approach to limit CRC progression, 
but this approach requires the identification of shared regulators of 
IL-17A expression in both cell types. One strategy may be the tar-
geting of RORγt—the master transcriptional regulator of IL-17A—via 
manipulating its degradation. RORγt protein expression levels are 
controlled by ITCH-mediated ubiquitination, and Itch knockout mice 
are more susceptible to AOM/dextran sodium sulfate (DSS)–induced 
tumorigenesis due to increased IL-17 production by CD4 T cells and 
γδ T cells.251 Small molecule inhibitors are being developed for sev-
eral autoimmune disorders, such as multiple sclerosis, psoriasis, and 
rheumatoid arthritis, where Th17 cells and γδ T cells drive pathology 
that could be repurposed for anti-cancer therapy.252
Whether the importance of IL-17–producing γδ T cells is con-
served in human cancer is controversial. Circulating Vγ9Vδ2 cells 
from healthy donors do not readily produce IL-17A, although they 
can be enticed to secrete this cytokine in vitro when given IL-23, 
IL-1β, TGFβ, and/or IL-7.34,253,254 Nevertheless, IL-17–producing 
γδ T cells are found in human CRC tissue, and these cells are more 
prevalent in tumors than in normal tissue.222,255-257 Their frequency 
positively correlates with tumor stage, tumor size, invasion, lymph 
node metastasis, vascular and lymphatic invasion, and immunosup-
pressive neutrophils.255 Interestingly, IL-17–producing γδ T cells out-
number Th17 cells in at least one cohort of CRC patients.255 Some 
IL-17–producing γδ T cells may have regulatory functions that sup-
press anti-tumor T cells and express CD39.257
The lack of knowledge surrounding the role of γδ T cells in CRC 
is partly related to the paucity of more sophisticated mouse mod-
els that incorporate other common CRC genetic mutations, such as 
KRAS, p53, and TGFβ signaling. New CRC models have recently been 
developed that should provide further insight into the pro-tumori-
genic role of γδ T cells.210 Some of these new models fully progress 
to the carcinoma stage and metastasize to distant organs, so they 
should allow researchers to dissect γδ T cell function at different 
stages of disease progression. A transplantation model with organ-
oids carrying mutations in Apc, Kras, Tgfbr2, and Trp53 genes demon-
strated that TGFβ signaling plays a critical role in colorectal cancer 
metastasis.213 In this study, combination treatment of TGFβ inhib-
itor and PD-L1 inhibitor improves survival of tumor-bearing mice 
and reduces metastasis formation. As γδ T cells can produce TGFβ 
and suppress cytotoxic CD8 T cells through PD-L1 expression,258 
γδ T cells might be involved in metastasis via immunosuppression in 
this CRC model. We reported on the ability of IL-17–producing γδ T 
cells to control immunosuppressive neutrophils in breast cancer and 
potentiate metastasis to the lung.236,249 Therefore, γδ T cells may 
also control pro-metastatic neutrophils in CRC. Recently, neutro-
phils were shown to promote liver metastasis in a new genetically 
engineered mouse model whose tumors are driven by mutations in 
KRAS, loss of p53, and overexpression of NOTCH1.212 From these 
new models, we may also learn additional mechanisms of tumor pro-
motion independent of IL-17 expression. γδ T cells can express galec-
tin-1 to suppress anti-tumor T cells in a Kras/p53 sarcoma model,259 
as well as IL-22 and amphiregulin (AREG) to stimulate epithelial cells 
in a Kras/p53 lung cancer model.250
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CELL S IN CRC
Prognostic indicators of disease progression are of key interest spe-
cifically in CRC, as the gold standard tumor burden/nodal status/
metastasis or TNM staging system is not sufficiently accurate prog-
nostic markers for stage II and stage III patients. In addition, approxi-
mately 25% of stage II and stage III patients relapse, despite the lack 
of evidence for residual cancer cells or distant metastasis following 
surgical resection.260,261 Moreover, TMN cannot predict response to 
chemotherapy. Attempts to refine or replace the TNM staging sys-
tem have given rise to the Immunoscore,262 which is based on the 
observation that T cells have a strong, favorable prognostic role in 
CRC. This originated from a study in 415 CRC patients showing that 
increased infiltration of CD3, CD8, or CD45RO (effector/memory) 
T cells at the tumor center or invasive margin, but particularly when 
high in both, is associated with greater disease-free survival.263 
Importantly, this analysis outperformed the TNM staging system. In 
follow-up studies using two independent cohorts of 602 combined 
patients, only 4.8% of the high Immunoscore group exhibited relapse 
after 5 years.264 Immunoscore can also be applied to lung and liver 
metastatic lesions to predict patient outcome.265 The Immunoscore 
encompasses tumor-infiltrating γδ T cells due to their expression of 
CD3 molecules. However, these cells represent less than 5% of the 
total CD3 population,222,266 so it is unclear whether their abundance 
actually contributes to the overall predictive power of Immunoscore 
in CRC. To date, a comprehensive histological analysis of the prog-
nostic power of γδ T cells in CRC has not been reported. Given the 
association of high Immunoscore with favorable outcome, one may 
speculate that γδ T cells will correlate with good prognosis, although 
increased intratumoral γδ T cells in breast and gallbladder correlate 
with poor prognosis.267,268
In a study from 2015 that is often quoted by the γδ T cell com-
munity to justify the use of anti-tumorigenic γδ T cells in cancer im-
munotherapy, γδ T cells were the best indicator of good prognosis, 
among every immune cell population in multiple tumor types.269 To 
arrive at this conclusion, about 18,000 human tumors including CRC 
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were analyzed for their composition of immune cells using a compu-
tational method called CIBERSORT that infers individual immune cell 
populations from bulk transcriptomic datasets. After pooling cancer 
types to determine global leukocyte prognostic patterns based on 
overall survival, this study found that myeloid cell populations were 
generally unfavorably prognostic, while lymphoid populations were 
more positive markers of patient outcome. Interestingly, γδ T cells 
scored highest in the favorable prognosis group across more than 20 
cancer types.269 However, the delineation of a γδ T cell gene signa-
ture from transcriptomic data by the CIBERSORT method has been 
challenged,270 because there is a significant overlap between the γδ 
T cell gene signature and other lymphocyte subsets. CIBERSORT re-
lies on a series of reference gene signatures derived from peripheral 
blood immune cells.271 When CIBERSORT was applied to Vγ9Vδ2 
cells purified from the peripheral blood of 12 healthy donors, there 
was significant overlap between CD8 T cells, CD4 T cells, and NK 
cells.270 Therefore, the CIBERSORT γδ T cell gene signature was 
refined to include 375 genes, which significantly improved spe-
cific detection of Vγ9Vδ2 cells. Further analysis showed that αβ T 
cell abundance in CRC correlates with TCR signaling, TLR signal-
ing, antigen processing, cytolytic activity, and interferon response 
pathways, whereas Vγ9Vδ2 abundance did not correlate with any of 
these pathways. Regardless, tumors with high infiltration of Vγ9Vδ2 
cells or αβ T cells associated with good outcome of CRC patients.270 
This observation was validated in a separate cohort of CRC patients 
using the same methodology.222 It would be interesting to learn the 
prognostic value of Vδ2— cells, particularly the gut-resident Vδ1 
subset, and the IL-17–producing subsets in those patient cohorts. 
Independent of γδ T cells, IL17A expression is associated with poor 
survival in CRC,222,272 but IL-17–producing γδ T cells are also associ-
ated with poor outcome in CRC.255,257
The simple presence of γδ T cells in CRC is not what dictates their 
contribution to tumorigenesis of course, but rather their functional 
capabilities, such as cytolytic activity. A quantitative measure of im-
mune cell cytolytic activity (CYT) has been developed using mRNA 
expression levels of two genes, granzyme A and perforin.273 In TCGA 
datasets, CYT is higher in normal colorectal tissue than colorectal 
tumor tissue with MSI expectantly exhibiting the highest CYT among 
all CRC subtypes.273-275 The CYT score is a favorable prognostic 
factor for both overall and disease-free survival. Interestingly, γδ T 
cells are more abundant in the CYT high colorectal tumors together 
with CD4 T cells, NK cells, and anti-tumorigenic macrophages, when 
compared to CYT low colorectal tumors.274,275 These γδ T cells are 
presumably Vγ9Vδ2 cells, since the original CIBERSORT method was 
used to identify them. Their association with CYT is perhaps not sur-
prising given that Vγ9Vδ2 cells are enriched in MSI tumors such as αβ 
T cells.222,276 Whether γδ T cells contribute to CYT score by directly 
producing granzyme A and perforin in CRC is unclear.
One area of CRC-specific oncology that needs further develop-
ment is the ability of γδ T cell subsets to predict response to T cell 
checkpoint inhibitor immunotherapy, such as anti-CTLA4 and an-
ti-PD-1. This is because γδ T cell subsets are biomarkers of immuno-
therapy response in other cancer types. In patients with melanoma 
that received ipilimumab (anti-CTLA4), the discernment between 
circulating levels of Vδ1 and Vδ2 cells is imperative, as the frequency 
of γδ T cells in peripheral blood of cancer patients versus healthy do-
nors is similar. However, when melanoma patients have low levels of 
Vδ1 cells or high levels of Vδ2 cells, overall survival—assessed from 
the first dose of ipilimumab—is positive.277 Another consideration 
for immunotherapy is whether γδ T cells either play a role in the im-
munotherapy-induced inflammatory side effects, such as colitis, or 
could serve as biomarkers for inflammation. A recent investigation 
into the mechanisms responsible for immunotherapy-driven colitis in 
melanoma patients showed that gut-resident γδ IELs are reduced in 
colitis patients when compared to patients on immunotherapy with-
out colitis or healthy tissue from patients undergoing colonoscopies. 
By contrast, infiltrating γδ T cells were unaffected in immunothera-
py-induced colitis.278
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γδ T cells are of increasing interest in cancer immunotherapy due to 
their potent cytotoxicity and ability to recognize MHC-unrestricted 
antigens. For solid tumors, case studies, and phase I trials in renal cell 
carcinoma, metastatic breast cancer and lung cancer suggest that 
Vγ9Vδ2 cell immunotherapy can significantly impact cancer pro-
gression in patients.279-282 This type of immunotherapy is also well-
tolerated.283,284 Therefore, considerable effort has been focused on 
preconditioning γδ T cells ex vivo to bolster their anti-tumorigenic 
functions before adoptive cell transfer into cancer patients. In many 
studies, IL-2 and zoledronate are used to expand Vγ9Vδ2 cells in 
vitro; however, zoledronate must be slowly diluted during expan-
sion because continuous exposure is toxic.280,281,285,286 Autologous 
Vγ9Vδ2 cells expanded in vitro with zoledronate have been given 
to CRC patients following surgery to remove pulmonary metastasis. 
These cells maintain their effector functions as determined by IFNγ 
production and CD107a expression during culture conditions,287 al-
though the efficacy of these Vγ9Vδ2 cells in controlling tumor pro-
gression was not reported. IL-23 in combination with zoledronate 
and IL-2 may further encourage cytotoxic functions from Vγ9Vδ2 
cells during expansion.220,288 The impact of synthetic phosphoan-
tigens on Vγ9Vδ2 cells has also been tested in patients with solid 
tumors, including CRC. Bromohydrin pyrophosphate (BrHPP, IPH 
1101) is one such synthetic phosphoantigen.289 The numbers of 
Vγ9Vδ2 cells extracted from cancer patients treated with BrHPP 
show an initial increase that was over time with subsequent BrHPP/
IL-2 treatments.290 Similarly, Vγ9Vδ2 cells from the peripheral blood 
of CRC patients that are expanded ex vivo with BrHPP and IL-2 
acquire an effector phenotype and show strong lytic activity spe-
cifically toward tumor cells in both a TCR- and NKG2D-mediated 
manner.291 Blocking B7-H3 on Vγ9Vδ2 cells increases colorectal 
cancer cell line killing in vitro and in vivo,224 suggesting that interfer-
ing with B7-H3 signaling may further improve cytotoxicity by these 
cells. Thus, Vγ9Vδ2 cells may provide a safe and effective form of 
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immunotherapy for CRC patients. Given that Vδ1 cells are consist-
ently shown to be more potent responders to CRC than Vγ9Vδ2 
cells, harnessing Vδ1 cells for immunotherapy in CRC and utilizing 
different γδ T cell subsets may also prove beneficial in patients.
Another strategy to boost Vγ9Vδ2 cell killing capacity is to increase 
their ability to recognize cancer cells. Given that the human Vγ9Vδ2 
subset shows cytotoxicity against CRC cell lines via IPP-stimulated 
activation of BTN3A1,160,221,226,292-294 inducing IPP accumulation will 
position BTN3A1 and BTN2A1 in the right conformational position for 
Vγ9Vδ2 cell recognition. Zoledronate sensitizes CRC cells to Vγ9Vδ2 
cell killing.226,295 Zoledronate allows the accumulation of IPP by block-
ing farnesyl pyrophosphate synthase so that IPP is not converted into 
cholesterol or ubiquinones. However, in order for Vγ9Vδ2 cell immu-
notherapy to be effective in CRC patients, the right patient population 
must first be selected. There are clues from the literature that p53 
status may be the key to patient selection. In CRC, breast and liver 
cancer cells, p53 suppresses mevalonate pathway–related enzymes, 
whereas p53-mutant or p53-deficient cells show elevated expres-
sion of mevalonate pathway–related enzymes.296-298 These observa-
tions would suggest that tumors with p53 mutations accumulate IPP, 
making them amenable to Vγ9Vδ2 cell immunotherapy. Conversely, 
colorectal tumors with wildtype p53 may need zoledronate treat-
ment to build up IPP in cancer cells and expose BTN3A1-BTN2A1 to 
Vγ9Vδ2 cells. The class of drugs known as statins also inhibits the me-
valonate pathway at the level of hydroxyl-methylglutaryl coenzyme 
A reductase (HMG-CoAR), an enzyme that converts HMG-CoA into 
mevalonate far upstream of IPP. While statins may induce apoptosis 
of p53-deficient CRC cells by starving cancer cells of ubiquinones,298 
CRC cells treated with statins may actually reduce Vγ9Vδ2 cell recog-
nition as IPP production will be prevented in these cells. p53 muta-
tions are extremely common in CRC where 34% of proximal tumors 
and 45% of distal colorectal tumors contain p53 abnormalities. Future 
studies will hopefully shed light on various ways that genetic makeup 
of CRC may be exploited for γδ T cell immunotherapy.
Other strategies to exploit the killing capacity of γδ T cells include 
bispecific antibodies, transduction of γδTCRs into αβ T cells (named 
T cells engineered with defined γδTCRs or TEGs),299,300 chimeric an-
tigen receptors (CARs),301,302 or specific expansion protocols for Vδ1 
cells (named Delta One T [DOT] cells).303 The development of these 
cell-based methods for solid tumors is still in its infancy. A bispe-
cific nanobody capable of activating Vγ9Vδ2 T cells while inhibiting 
the activation of EGFR has shown efficacy in CRC cell lines.304 This 
type of immunotherapy may prove extremely useful in patients with 
KRAS-mutant tumors resistant to the EGFR-targeted antibodies 
cetuximab or panitumumab.305
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CONCLUSIONS
Given their prominence in gut tissue, the various subsets of γδ T 
cells should receive more attention in cancer research to understand 
their behavior during tumorigenesis and their potential for cancer 
immunotherapy. Recent data have shed light on these underappreci-
ated cells, but their function in CRC is still largely unexplored. The 
complex nature of γδ T cell subsets includes both pro- and anti-tu-
morigenic roles in cancer progression, providing new opportunities 
for therapeutic intervention. The seminal works on the importance 
of BTN/BTNL proteins in the regulation of γδ T cells and the high 
homology between mouse and human species open up new avenues 
for γδ T cell biology in the context of CRC. To gain new knowledge 
and discover new biology, more sophisticated CRC mouse models 
that capture CRC development from tumor initiation to metastasis 
formation should be employed. Along these lines, the existing mouse 
models for in vivo imaging should be applied to the cancer context to 
determine how γδ T cells move in and around gut tumors. Organoids 
or tissue explants derived from human tumors that are cocultured 
with human γδ T cell subsets will also be valuable. Overall, the tools 
currently available to manipulate γδ T cell subsets are limited, but 
they will be necessary to fully understand their pro- and anti-tumor-
igenic functions. These models may generate additional data in less-
studied areas of γδ T cell biology including immunometabolism. In 
regard to cancer immunotherapy, we must learn which γδ T cell strat-
egy is most efficacious and which patient population to treat with γδ 
T cell therapy. Together, these new methodologies and insights will 
uncover various ways to exploit γδ T cell biology for CRC treatment.
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